Myomo Hosts Investor & Analyst Day for Growth

Myomo ( (MYO) ) just unveiled an announcement.

On June 18, 2025, Myomo, Inc. hosted an Investor & Analyst Day, providing an in-depth overview of its business model and long-term financial aspirations. The event highlighted the company’s efforts to improve lead generation, Medicare Advantage reimbursement, and manufacturing capacity. Management shared plans to enhance products and increase production, aiming for $100 million in annual revenue by 2028. The event also showcased Myomo’s commitment to expanding its market presence and improving patient outcomes through innovative medical robotics solutions.

The most recent analyst rating on (MYO) stock is a Buy with a $9.50 price target. To see the full list of analyst forecasts on Myomo stock, see the MYO Stock Forecast page.

Spark’s Take on MYO Stock

According to Spark, TipRanks’ AI Analyst, MYO is a Neutral.

Myomo’s stock score reflects a blend of promising revenue growth and positive earnings call sentiment, countered by significant challenges such as lack of profitability and bearish technical indicators. The strategic board transition adds a slight positive outlook but does not offset the primary concerns of profitability and cash flow. Overall, the stock is positioned in a moderate range, with potential for improvement contingent on operational efficiencies and market conditions.

To see Spark’s full report on MYO stock, click here.

More about Myomo

Myomo, Inc. is a wearable medical robotics company that develops and markets the MyoPro product line, a powered upper-limb orthosis designed to restore function to the weakened or paralyzed arms of patients with neurological disorders and upper-limb paralysis. Headquartered in Burlington, Massachusetts, Myomo serves patients across the U.S. and internationally.

Average Trading Volume: 467,728

Technical Sentiment Signal: Strong Sell

Current Market Cap: $100.4M

Find detailed analytics on MYO stock on TipRanks’ Stock Analysis page.